7/12/2013

Merrimack Pharmaceuticals could raise $125 million through stock offering and sale of convertible senior notes. The Cambridge, Mass.-based firm will mainly use the proceeds to support clinical studies, regulatory submissions and pre-approval commercial work for MM-398, its experimental drug for metastatic pancreatic cancer.

Related Summaries